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ABSTRACT: The Erwinia ligand-gated ion channel (ELIC) is a bacterial homologue of
eukaryotic Cys-loop ligand-gated ion channels. This protein has the potential to be a useful
model for Cys-loop receptors but is unusual in that it has an aromatic residue (Phe) facing
into the pore, leading to some predictions that this protein is incapable of ion ﬂux.
Subsequent studies have shown this is not the case, so here we probe the role of this residue
by examining the function of the ELIC in cases in which the Phe has been substituted with a
range of alternative amino acids, expressed in Xenopus oocytes and functionally examined.
Most of the mutations have little eﬀect on the GABA EC50, but the potency of the weak pore-
blocking antagonist picrotoxinin at F16′A-, F16′D-, F16′S-, and F16′T-containing receptors
was increased to levels comparable with those of Cys-loop receptors, suggesting that this
antagonist can enter the pore only when residue 16′ is small. T6′S has no eﬀect on
picrotoxinin potency when expressed alone but abolishes the increased potency when combined with F16′S, indicating that the
inhibitor binds at position 6′, as in Cys-loop receptors, if it can enter the pore. Overall, the data support the proposal that the
ELIC pore is a good model for Cys-loop receptor pores if the role of F16′ is taken into consideration.
The Erwinia ligand-gated ion channel (ELIC) is a cation-selective GABA-gated ion channel originally identiﬁed in
the enterobacterium Erwinia chrysanthemii. ELIC shares
considerable structural homology with eukaryotic Cys-loop
receptors, a class of neurotransmitter-gated ion channels that
underpin fast synaptic transmission. One of the major problems
in understanding the mechanisms of action of this family of
channels is the paucity of high-resolution structures. An X-ray
crystal structure of ELIC was determined in 2008, and the
following year, the structure of the Gloeobacter ligand-gated ion
channel or GLIC, from the bacterium Gloeobacter violaceous, was
determined.1−3 These bacterial receptors were found to share
many structural features with Cys-loop receptors, although they
do not possess an N-terminal α-helix, an intracellular domain, or
the disulﬁde-bonded loop that gives the eukaryotic family its
name. GLIC is activated by protons and ELIC by a range of small
amine molecules, including GABA.4,5 The potency of GABA at
ELIC is low compared to those of its eukaryotic counterparts,
but work on bacterial receptors in other systems6,7 suggests that
even if the potencies are not in the same range, their mechanisms
of action at homologous proteins are similar, making ELIC
an attractive model system for understanding the molecular
mechanisms of Cys-loop receptors.
ELIC shows a low level of sequence identity with Cys-loop
receptors overall, but many key features are conserved. The
functional receptor is pentameric, with a large extracellular
domain (ECD) that contains the ligand binding site and a
transmembrane domain (TMD) consisting of four α-helices
from each subunit (termedM1−M4). The M2 α-helix from each
subunit lines the pore, and this region in particular is highly
homologous in sequence (>60%) to Cys-loop receptors. It is,
however, unusual in that it contains a large aromatic Phe residue
that points into the pore lumen (Figure 1). This was proposed as
a reason that ELIC was not functional in early studies that sought
to identify an activating ligand, a hypothesis supported by studies
of molecular dynamics and Brownian dynamics.8 Subsequent
studies have shown that ELIC is readily opened by a range of
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Figure 1. Alignment of M2 channel-lining residues for ELIC with
eukaryotic Cys-loop receptors and a cartoon showing two of the ﬁve
pore-forming transmembrane α-helices, highlighting the location of
F16′ and L9′. As is common for these receptors, a prime notation is used
to facilitate comparison between diﬀerent subunits, with 0′ being the
conserved charged residue at the start of M2. Accession numbers are
P0C7B7 for ELIC, P46098 for 5-HT3A, P02708 for nACh α1, P23415
for Gly α1, and P14867 for GABAA α1.
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amine molecules,4,5 and even when mutations are introduced to
prevent desensitization, the structure of the pore is such that the
Phe is present in the lumen.9 As the pore has been used as a
model for Cys-loop receptors, the aim of this study was to probe
the role of this Phe residue, to determine if the ELIC channel is
indeed representative of Cys-loop receptor pores.
■ MATERIALS AND METHODS
Materials. Picrotoxinin (PXN) was kindly provided by
R. Duke (University of Sydney, Sydney, Australia) after separa-
tion and puriﬁcation by recrystallization following short column
vacuum chromatography from picrotoxin purchased from Sigma-
Aldrich Australia. All other regents were from Sigma-Aldrich and
of the highest grade that could be obtained.
Cell Culture and Oocyte Maintenance. Xenopus laevis
oocyte-positive females were purchased from NASCO (Fort
Atkinson, WI) and maintained according to standard methods.
Harvested stage V and VI Xenopus oocytes were washed in
four changes of Ca2+-free ND96 [96 mM NaCl, 2 mM KCl,
1 mM MgCl2, and 5 mM HEPES (pH 7.5)], defolliculated in
1.5 mg mL−1 collagenase type 1A for approximately 2 h, washed
again in four changes of ND96, and stored in ND96 at 16 °C
containing 2.5 mM sodium pyruvate, 50 mM gentamycin, and
0.7 mM theophylline.
Receptor Expression. ELIC (GenBank accession number
ADN00343.1) was kindly provided by C. Ulens. For expression
in Xenopus oocytes, it was cloned into pGEMHE with the
signal sequence of the human α7 nACh receptor. Site-directed
mutagenesis was performed with the QuikChange mutagenesis
kit (Stratagene, La Jolla, CA). cRNAwas transcribed in vitro from
the linearized pGEMHE cDNA template using the mMessage
mMachine T7 transcription kit (Ambion, Austin, TX). Stage V
and VI oocytes were injected with 20 ng of cRNA, and currents
were recorded 1−3 days postinjection.
Electrophysiology. Using two-electrode voltage clamp,
Xenopus oocytes were clamped at −60 mV using an OC-725
ampliﬁer (Warner Instruments, Hamden, CT), Digidata 1322A,
and the Strathclyde Electrophysiology Software Package
(Department of Physiology and Pharmacology, University of
Strathclyde, Glasgow, U.K.). Currents were recorded at 5 kHz
and ﬁltered at a frequency of 1 kHz. Microelectrodes were
fabricated from borosilicate glass (GC120TF-10, Harvard
Apparatus, Edenbridge, Kent, U.K.) using a one-stage horizontal
pull (P-87, Sutter Instrument Co., Novato, CA) and ﬁlled with
3MKCl. Pipette resistances ranged from 1.0 to 2.0MΩ. Oocytes
were perfused with ND96 at a constant rate of 12 mLmin−1 with
complete solution exchange within 5 s. Drug application was
accomplished via a simple gravity-fed system calibrated to run at
the same rate. Inhibition by test compounds was measured at the
GABA EC50 for each mutant.
Analysis and curve ﬁtting were performed using Prism version
4.03 (GraphPad Software, San Diego, CA). Concentration−
response data for each oocyte were normalized to the maximal
current for that oocyte and the mean ± standard error of the
mean (SEM) for a series of oocytes pooled and plotted against
agonist or antagonist concentration and iteratively ﬁt to the four-
parameter logistic equation. Statistical analysis was performed
using a Student’s t test.
Docking.The three-dimensional structure of PXNwas extracted
from the Cambridge Structural Database (reference code PXN =
CIBCUL10), and the protonated form was constructed using
Chem3D Ultra 7.0 (CambridgeSoft, PerkinElmer, Waltham,
MA) and energy-minimized using the MM2 force ﬁeld. Docking
was as described previously10 using an ELIC crystal structure
(entry 2VL0) downloaded from the RCSB Protein Data Bank.
Docking of PXN into ELIC was conducted using GOLD 3.0
(The Cambridge Crystallographic Data Centre, Cambridge,
U.K.). The binding site was constrained as a docking sphere with
a 20 Å radius surrounding either the Cα atom of residue 6′ or 16′
in chains A and C. Ten genetic algorithm runs were performed
on each docking exercise using default parameters. The structures
were visualized using PyMOL version 1.3 and ViewerLite
version 5.0.
■ RESULTS
Activation of ELIC by GABA. ELIC has been previously
shown to be activated by a range of small molecules containing
an amine group, including cysteamine and GABA.4,5 Here we
used GABA, and its application produced large, concentration-
dependent, reversible inward currents. Plotting peak current
amplitude against a range of GABA concentrations yielded an
EC50 of 1.6 mM (pEC50 = 2.78 ± 0.04; n = 7) and a Hill slope of
2.5 ± 0.7, similar to the values found in other studies.4,5
Mutant Receptors. To explore the role of phenylalanine in
the pore of ELIC we substituted this residue with a selection of
other amino acids covering a range of sizes and hydrophobicities,
and we also introduced negatively charged residues as molecular
dynamic simulation data have suggested that this will favor the
open channel.8 We observed some increases in EC50 compared
to those of wild-type receptors when we substituted Phe16′ with
Glu, Leu, and Thr, but there were no signiﬁcant changes to EC50
with Ala, Asp, Gln, Trp, or Tyr (Table 1). These data show
many residues are tolerated at this location, and that no speciﬁc
chemical properties (such as aromaticity or hydrophobicity) are
required. The negatively charged amino acids Glu and Asp have
diﬀerent eﬀects: Asp at this position yielded an EC50 similar to
those of wild-type receptors, while Glu caused a 16-fold increase
in EC50. As residue 16′ is some distance from the binding site,
these data suggest that it may play some minor role in channel
gating (as the term EC50 includes contributions from both
binding and gating), although we cannot rule out the fact that this
Table 1. Parameters Derived from GABA Concentration−
Response Curves of Wild-Type and Mutant ELIC
GABA EC50
pEC50 EC50 (mM) nH n
wild type 2.78 ± 0.04 1.6 2.5 ± 0.7 7
Q2′A NRa 3
Q2′N 2.74 ± 0.02 1.8 2.6 ± 1.3 3
T6′A 3.07 ± 0.01 0.8 2.1 ± 0.1 3
T6′S 2.75 ± 0.02 1.8 2.7 ± 0.3 3
F16′A 2.31 ± 0.08 4.9 3.0 ± 0.5 4
F16′D 2.68 ± 0.10 2.1 2.5 ± 0.3 5
F16′E 1.59 ± 0.05b 26 1.3 ± 0.2 3
F16′Q 2.11 ± 0.10 7.1 2.3 ± 0.6 3
F16′L 1.29 ± 0.03b 51 1.6 ± 0.2 5
F16′S 2.15 ± 0.06b 7.1 2.5 ± 0.6 4
F16′T 1.94 ± 0.04b 11 1.8 ± 0.3 3
F16′W 2.64 ± 0.02 2.3 3.6 ± 0.5 3
F16′Y 2.12 ± 0.10 7.5 2.1 ± 0.3 5
F16′S/T6′S 2.19 ± 0.09 6.4 2.2 ± 0.7 3
aNo response at 100 mM GABA. bSigniﬁcantly diﬀerent from that of
the wild type (p < 0.05).
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and some of the other mutations may cause a global structural
change that aﬀects the binding site. However, as many pore-
lining substitutions in many Cys-loop receptors have not been
reported to cause a global structural change, we consider this less
likely. The largest change in EC50 was for Leu, which is surprising
as Leu is found at position 16′ in many nACh receptor subunits,
but these data are consistent with the fact that the structure in this
region diﬀers from that of its eukaryotic relatives.
We also made mutations at the Q2′ and T6′ positions. Q2′N,
T6′A and T6′S mutations caused no change to the GABA EC50
values. Q2′A receptors did not respond to application of 100mM
GABA suggesting that they were either non-functional or not
expressed. F16′S in combination with T6′S (T6′S/F16′S)
caused no signiﬁcant increase in EC50.
PXN Inhibition. Wild-type ELIC was inhibited by
PXN with an IC50 of 72 μM, similar to previous ﬁndings.
10
This value is considerably lower than values reported for GLIC
and other Cys-loop receptors where it is known to bind in the
pore and suggests that PXN mediates its action in ELIC by
binding elsewhere on the protein. Given the homology between
the M2 regions of all these receptors, it is surprising that PXN
cannot bind, and thus, we considered whether a PXN binding site
could exist in the pore and whether PXN cannot access this site
because of the narrow entrance resulting from the presence of a
ring of Phe residues at position 16′. We therefore examined the
potency of PXN over a range of mutant receptors where the size
of the residue was varied. These data showed that substitution
with residues smaller than Phe increased PXN potency (Table 2, 3
and Figure 2), resulting in IC50 values more similar to those
observed with GLIC and Cys-loop receptors. A plot of pIC50
versus side chain size (Figure 4) shows a distinct relationship
(R2 = 0.7), supporting our hypothesis, although there are some
anomalies, such as the relatively high IC50 for F16′A; we
speculate that this may be due to extra ﬂexibility in this region
caused by insertion of a small residue.
Combining the F16′S and T6′Smutations ablated the increase
in PXN potency, indicating that even when PXN can access the
pore, it has speciﬁc binding requirements which involve T6′
(Table 3).
Table 2. Picrotoxinin Potencies of Wild-Type and Mutant
ELICsa
pIC50 IC50 (μM) nH n
wild type 4.14 ± 0.05 72 1.3 ± 0.3 3
Q2′N 4.36 ± 0.07 44 1.6 ± 0.3 3
T6′A 4.02 ± 0.05 95 1.8 ± 0.4 3
T6′S 4.17 ± 0.08 68 1.3 ± 0.3 3
F16′A 4.78 ± 0.08b 16 1.0 ± 0.2 5
F16′D 5.03 ± 0.11b 9.4 1.0 ± 0.2 3
F16′W 4.28 ± 0.08 52 1.3 ± 0.3 4
F16′S 5.35 ± 0.07b 4.5 1.3 ± 0.3 3
F16′T 5.14 ± 0.07b 7.2 0.9 ± 0.1 3
F16′E 4.57 ± 0.12 26.9 0.6 ± 0.1 3
aData are means ± SEM. bSigniﬁcantly diﬀerent from that of the wild
type (p < 0.05).
Figure 2. Example traces of PXN inhibition of wild-type and mutant
ELIC. (A) Co-application of GABA EC50 with 100 μM PXN inhibits
∼50% of the wild-type and F16′W responses but completely abolishes
the F16′S response. (B) Increasing concentrations of PXN sequentially
diminish the GABA-elicited response (here 0, 10, 100, and 300 μMPXN
with 0.8 mM GABA). Data such as these were used to create the
inhibition curves shown in Figure 3.
Figure 3. PXN inhibition of wild-type and mutant ELIC. (A) Inhibition
curves of wild-type and F16′ mutant ELIC responses. (B) Inhibition
curves of wild-type and T6′ mutant ELIC responses. Data are means ±
SEM (n = 3−6). Parameters obtained from these curves are listed in
Tables 2 and 3.
Table 3. Picrotoxinin and Proadifen Potencies Are
Diﬀerentially Modiﬁed in Pore-Lining Mutant ELICsa
PXN proadifen
pIC50 IC50 (μM) pIC50 IC50 (μM)
wild type 4.14 ± 0.05 72 5.09 ± 0.04 8.1
T6′S 4.17 ± 0.08 68 5.59 ± 0.12 2.9
F16′S 5.35 ± 0.07b 4.5 5.29 ± 0.04 5.1
T6′S/F16′S 4.36 ± 0.05 44 6.03 ± 0.18 0.9
aData are means ± SEM (n = 3−6). bSigniﬁcantly diﬀerent from that
of the wild type (p < 0.05).
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Proadifen Inhibition. To further conﬁrm our hypothesis
that high-aﬃnity inhibition by PXN depends on it being able to
access its binding site deep in the pore and was not due to changes
in other properties caused by the mutations, we examined
inhibition by another compound that does not act via a pore
binding site. Proadifen was one of the most potent inhibitors we
previously identiﬁed in ELIC with an IC50 of 8 μM.
10 Unlike that
of PXN, the potency of this compound did not change when we
examined its eﬀects in F16′S, T6′S and F16′S/T6′Smutant ELIC
(Table 3), consistent with a site of action that is not in the ion-
permeable pore. These data also support our assumption that
there has been no global change in the structure of ELIC caused
by the pore-lining mutations.
Docking Data. The binding orientation and location of PXN
have been studied in a number of Cys-loop receptors using ligand
docking (with homology models where structures are not
known) and have shown that it is deep in the pore, close to
positions−2′, 2′, and/or 6′. These data allow potential molecular
interactions to be identiﬁed and tested. As the structure of ELIC
is known, it provides the opportunity for similar in silico studies
here, although some caution must be applied, as the structure
most likely is in the closed state. We docked PXN into the ELIC
pore and identiﬁed possible binding poses in two regions: above
F16′ and close to position 6′. Examination of multiple poses for
those molecules bound close to F16′ revealed that the locations
of PXN were broadly similar but that there were some variations
in orientations; a similar ﬁnding was observed for PXN bound
close to position 6′ (see Figure 5). One orientation of PXN close
to position 6′ is shown in Figure 6, where it can be seen to be
stabilized by several hydrogen bonds with the Thr residues at
position 6′, which is consistent with a high-aﬃnity binding site at
this location. These data therefore support our hypothesis that
PXN could bind in the pore with high aﬃnity at a location that
would be expected given its homology to Cys-loop receptor
pores.
■ DISCUSSION
ELIC is a cationic GABA-gated bacterial ligand-gated ion
channel that is functionally and structurally similar to vertebrate
GABA-gated receptors.10 ELIC has the advantage of a known
high-resolution structure, making it a potentially useful system
for understanding structure−function relationships in eukaryotes.
However, the ELIC pore is unusual as it possesses a Phe residue
at position 16′ that faces into the channel lumen (Figure 1);
this might be expected to impede channel access. Here we show
that this is the case for the channel blocking compound PXN,
but increasing or decreasing the size of residue 16′ does not
cause major changes to GABA-induced activation, indicating that
the properties of the residue at this location do not signiﬁcantly
modify receptor function.
We have previously shown that many Cys-loop receptor
pore blockers also block the pores of ELIC and GLIC but are
generally less potent at ELIC.10,11 Docking studies indicate that
the 2′ and/or 6′ channel-lining residues are likely binding sites
for many of these compounds in ELIC, and there are many
mutagenesis studies in Cys-loop receptors that demonstrate the
importance of these two residues (e.g., refs 12−15). Similarly,
mutations of residues 2′ and 6′ in ELIC abolish inhibition by
α-endosufan, one of the most potent noncompetitive antagonists
of this receptor, supporting a binding location close to these two
residues. However, despite the similarity of pore-lining residues,
PXN is more than 1 order of magnitude less potent in ELIC than
in GLIC, where it has a potency similar to those of Cys-loop
receptors.10,11 The data presented here provide a solution to this
apparent conundrum, as substitution of Phe16′ with a smaller
residue such as Ser results in an IC50 for PXN (4.5 μM) that is
similar to that observed for GLIC (2.6 μM) and those observed
for Cys-loop receptors.16,17 Substitution with a larger residue,
such as Trp, has no eﬀect on the PXN IC50. Our data therefore
suggest that Phe at position 16′ sterically blocks the access of
large pore binding antagonist molecules to the channel, while
smaller residues do not. The fact that high concentrations of
PXN block wild-type ELIC suggests that it has a low-aﬃnity site
of action elsewhere on the protein, as has been also suggested for
GABAA receptors (e.g., ref 18).
Our data support our in silico studies that indicate the PXN
pore binding site is close to position 6′: mutation of this residue
has a signiﬁcant eﬀect on potency only when the residue is
accompanied by an F16′S mutation, suggesting that PXN can
Figure 4. pIC50 vs side chain volume. Volumes are calculated from the
surface area of the side chain.26
Figure 5. Overlay of 10 docked poses for PXN in the ELIC pore. The
channel is seen from the side, and the ligands are located above F16′
(left) or close to the residues at position 6′ (right).
Figure 6. Example docked pose for PXN in the ELIC channel. PXN is
located close to the Thr residues at position 6′, where it is stabilized by
hydrogen bonds. The channel is seen from the top looking down toward
the cell interior.
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enter the pore and bind close to residue 6′ only when there is
a small residue at position 16′. A site of action at position 6′ is
consistent with the eﬀects of mutating homologous residues in
5-HT3, GABA, and glycine receptors; in these proteins, altera-
tions to residue 6′ have signiﬁcant eﬀects on the sensitivity of
PTX,15,16,19 and these results are therefore similar to the results
we obtained in our modiﬁed ELIC. It should be noted, however,
that in GluCl picrotoxin may bind in a slightly diﬀerent location,
as the structural data reveal it is located further to the intracellular
side of the pore, close to residue −2′.20
We also probed inhibition by the local anesthetic proadifen.
This is not a classic Cys-loop channel blocker, although inhibitory
eﬀects have been reported.21 The IC50 values for proadifen did
not change much with any of the pore-lining mutations. These
data support the proposal that proadifen stabilizes the
desensitized state of the receptor by acting at a site outside the
channel pore, as has been proposed for nACh receptors,21 and
also supports our suggestion that the pore mutations do not
globally change ELIC structure. Binding sites outside the pore
have been identiﬁed using mutagenesis, photolabeling in
Cys-loop receptors, and crystal structures of ELIC and GLIC
bound with the general anesthetics bromoform, propofol, and
desﬂuorane.22−24
Our data also reveal that F16′ can be substituted with residues
that have quite distinct chemical properties without having major
eﬀects on EC50 values, as previously shown for an F16′A mutant
(<10-fold change in cysteamine EC50), indicating that the residue
at this location does not signiﬁcantly aﬀect receptor function.
The largest changes we observed in EC50 (32- and 16-fold) were
for F16′L and F16′E, respectively. An increase with F16′L was
unexpected as residue 16′ is Leu in many Cys-loop receptors.
We speculate it may be less favorable in ELIC because of the
adjacent Tyr: recent studies have shown an engineered ring of
F16′ residues in the nACh receptor results in a novel refractory
conformation; however, in combination with an engineered ring
of Y17′ residues, there was a high open probability even in the
absence of ligand.25 Thus, the context of amino acids in the pore
is critical in this region.
The increase observed for the F16′E alteration was less
unexpected: charged residues are rarely found lining Cys-loop
pores, where presumably they could inhibit ion ﬂux (e.g., by
repelling or binding to charged ions passing through the
channel), or they may be thermodynamically unfavorable (e.g.,
similar charges may face each other). Nevertheless, a recent
molecular dynamics study probing the possible eﬀect of F16′E
in ELIC concluded that such an alteration would have a favorable
eﬀect on the receptor: it suggested that the pore would be
more hydrated, and the protein would have a more dynamic
channel, exhibiting moremovement of the pore-lining α-helices.8
However, our observed increase in EC50 suggests it is less
favorable. We did not observe a similar increase with F16′D,
suggesting that the longer side chain of Glu is responsible.
Substitutions with Ser and Thr also caused small increases
in EC50, but all were <10-fold, indicating no major eﬀect.
Replacement with Trp had no eﬀect, demonstrating that there is
suﬃcient space at this location to accommodate a residue even
larger than Phe.
In conclusion, we have demonstrated that the F16′ residue at
the extracellular end of the ELIC pore does not play a major role
in the function of the protein, as its replacement with a range of
other amino acids has no major eﬀect on GABA-activated
currents. This residue may, however, prevent access of large,
pore-blocking antagonists from reaching their binding sites lower
in the channel. Overall, our data can explain why channel
blockers have lower potencies in ELIC than at either GLIC or
Cys-loop receptors and show that using ELIC as a model for
interactions with such compounds (for in silico and functional
studies) is likely to be more accurate if their entry into the pore is
permitted by substitutions of F16′.
■ AUTHOR INFORMATION
Corresponding Author
*Department of Biochemistry, Tennis Court Road, Cambridge
CB2 1QW, U.K. E-mail: sl120@cam.ac.uk. Telephone: (+44)
1223 765950. Fax: (+44)1223 333345.
Funding
This project was supported by the Wellcome Trust Grant 81925
to S.C.R.L. S.C.R.L. is a Wellcome Trust Senior Research Fellow
in Basic Biomedical Studies. M.A. is funded by a Yousef Jameel
Scholarship. D.A.W. was funded by an MRC studentship.
Notes
The authors declare no competing ﬁnancial interest.
■ ABBREVIATIONS
nACh, nicotinic acetylcholine; AChBP, acetylcholine binding
protein; GABA, γ-aminobutyric acid; ELIC, Erwinia ligand-gated
ion channel; GLIC, Gloeobacter ligand-gated ion channel; PXN,
picrotoxinin; ACh, acetylcholine; 5-HT, 5-hydroxytryptamine.
■ REFERENCES
(1) Bocquet, N., Nury, H., Baaden, M., Le Poupon, C., Changeux, J. P.,
Delarue, M., and Corringer, P. J. (2009) X-ray structure of a pentameric
ligand-gated ion channel in an apparently open conformation. Nature
457, 111−114.
(2) Hilf, R. J., and Dutzler, R. (2009) Structure of a potentially open
state of a proton-activated pentameric ligand-gated ion channel. Nature
457, 115−118.
(3) Hilf, R. J., and Dutzler, R. (2008) X-ray structure of a prokaryotic
pentameric ligand-gated ion channel. Nature 452, 375−379.
(4) Spurny, R., Ramerstorfer, J., Price, K., Brams, M., Ernst, M., Nury,
H., Verheij, M., Legrand, P., Bertrand, D., Bertrand, S., Dougherty, D. A.,
de Esch, I. J., Corringer, P. J., Sieghart, W., Lummis, S. C., and Ulens, C.
(2012) Pentameric ligand-gated ion channel ELIC is activated by GABA
and modulated by benzodiazepines. Proc. Natl. Acad. Sci. U.S.A. 109,
E3028−E3034.
(5) Zimmermann, I., and Dutzler, R. (2011) Ligand Activation of the
Prokaryotic Pentameric Ligand-Gated Ion Channel ELIC. PLoS Biol. 9,
e1001101.
(6) Singh, S. K., Yamashita, A., and Gouaux, E. (2007) Antidepressant
binding site in a bacterial homologue of neurotransmitter transporters.
Nature 448, 952−956.
(7) Zhou, Z., Zhen, J., Karpowich, N. K., Goetz, R. M., Law, C. J., Reith,
M. E., andWang, D. N. (2007) LeuT-desipramine structure reveals how
antidepressants block neurotransmitter reuptake. Science 317, 1390−
1393.
(8) Cheng, X., Ivanov, I., Wang, H., Sine, S. M., and McCammon, J. A.
(2009) Molecular-dynamics simulations of ELIC: A prokaryotic
homologue of the nicotinic acetylcholine receptor. Biophys. J. 96,
4502−4513.
(9) Gonzalez-Gutierrez, G., Lukk, T., Agarwal, V., Papke, D., Nair, S.
K., and Grosman, C. (2012) Mutations that stabilize the open state of
the Erwinia chrisanthemi ligand-gated ion channel fail to change the
conformation of the pore domain in crystals. Proc. Natl. Acad. Sci. U.S.A.
109, 6331−6336.
(10) Thompson, A. J., Alqazzaz, M., Ulens, C., and Lummis, S. C.
(2012) The pharmacological profile of ELIC, a prokaryotic GABA-gated
receptor. Neuropharmacology 63, 761−767.
Biochemistry Article
dx.doi.org/10.1021/bi5008035 | Biochemistry 2014, 53, 6183−61886187
(11) Alqazzaz, M., Thompson, A. J., Price, K. L., Breitinger, H. G., and
Lummis, S. C. (2011) Cys-loop receptor channel blockers also block
GLIC. Biophys. J. 101, 2912−2918.
(12) Hawthorne, R., and Lynch, J. W. (2005) A picrotoxin-specific
conformational change in the glycine receptor M2-M3 loop. J. Biol.
Chem. 280, 35836−35843.
(13) Sedelnikova, A., Erkkila, B. E., Harris, H., Zakharkin, S. O., and
Weiss, D. S. (2006) Stoichiometry of a pore mutation that abolishes
picrotoxin-mediated antagonism of the GABAA receptor. J. Physiol. 577,
569−577.
(14) Buhr, A., Wagner, C., Fuchs, K., Sieghart, W., and Sigel, E. (2001)
Two novel residues in M2 of the γ-aminobutyric acid type A receptor
affecting gating by GABA and picrotoxin affinity. J. Biol. Chem. 276,
7775−7781.
(15) Yang, Z., Cromer, B. A., Harvey, R. J., Parker, M. W., and Lynch, J.
W. (2007) A proposed structural basis for picrotoxinin and picrotin
binding in the glycine receptor pore. J. Neurochem. 103, 580−589.
(16) Das, P., and Dillon, G. H. (2005) Molecular determinants of
picrotoxin inhibition of 5-hydroxytryptamine type 3 receptors. J.
Pharmacol. Exp. Ther. 314, 320−328.
(17) Thompson, A. J., Duke, R. K., and Lummis, S. C. (2011) Binding
Sites for Bilobalide, Diltiazem, Ginkgolide, and Picrotoxinin at the 5-
HT3 Receptor. Mol. Pharmacol. 80, 183−190.
(18) Carpenter, T. S., Lau, E. Y., and Lightstone, F. C. (2013)
Identification of a possible secondary picrotoxin-binding site on the
GABAA receptor. Chem. Res. Toxicol. 26, 1444−1454.
(19) Erkkila, B. E., Sedelnikova, A. V., and Weiss, D. S. (2008)
Stoichiometric pore mutations of the GABAAR reveal a pattern of
hydrogen bonding with picrotoxin. Biophys. J. 94, 4299−4306.
(20) Hibbs, R. E., and Gouaux, E. (2011) Principles of activation and
permeation in an anion-selective Cys-loop receptor.Nature 474, 54−60.
(21) Spitzmaul, G., Gumilar, F., Dilger, J. P., and Bouzat, C. (2009)
The local anaesthetics proadifen and adiphenine inhibit nicotinic
receptors by different molecular mechanisms. Br. J. Pharmacol. 157,
804−817.
(22) Jayakar, S. S., Dailey, W. P., Eckenhoff, R. G., and Cohen, J. B.
(2013) Identification of propofol binding sites in a nicotinic
acetylcholine receptor with a photoreactive propofol analog. J. Biol.
Chem. 288, 6178−6189.
(23) Nury, H., Van Renterghem, C., Weng, Y., Tran, A., Baaden, M.,
Dufresne, V., Changeux, J. P., Sonner, J. M., Delarue, M., and Corringer,
P. J. (2010) X-ray structures of general anaesthetics bound to a
pentameric ligand-gated ion channel. Nature 469, 428−431.
(24) Spurny, R., Billen, B., Howard, R. J., Brams, M., Debaveye, S.,
Price, K. L., Weston, D. A., Strelkov, S. V., Tytgat, J., Bertrand, S.,
Bertrand, D., Lummis, S. C., and Ulens, C. (2013) Multisite Binding of a
General Anesthetic to the Prokaryotic Pentameric Erwinia chrysanthemi
Ligand-gated Ion Channel (ELIC). J. Biol. Chem. 288, 8355−8364.
(25) Gonzalez-Gutierrez, G., andGrosman, C. (2010) Bridging the gap
between structural models of nicotinic receptor superfamily ion
channels and their corresponding functional states. J. Mol. Biol. 403,
693−705.
(26) Richards, F. M. (1977) Areas, volumes, packing and protein
structure. Annu. Rev. Biophys. Bioeng. 6, 151−176.
Biochemistry Article
dx.doi.org/10.1021/bi5008035 | Biochemistry 2014, 53, 6183−61886188
